QL1706

Overview

QL1706 is an investigational bispecific antibody co-targeting PDCD1 (PD-1) and CTLA4. It is evaluated in nasopharyngeal carcinoma (NPC) and other solid tumors.

Evidence in the corpus

• QL1706 bispecific PD-1×CTLA-4 antibody listed among investigational dual checkpoint blocking strategies targeting compensatory CTLA-4 upregulation in PD-1/PD-L1-refractory R/M NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.